World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 March 2012
Main ID:  EUCTR2006-004784-58-DE
Date of registration: 11/03/2008
Prospective Registration: Yes
Primary sponsor: University of Leuven
Public title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease - ACTIF
Scientific title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease - ACTIF
Date of first enrolment: 27/05/2008
Target sample size: 25
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004784-58
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no  
Phase: 
Countries of recruitment
Belgium France Germany United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Inclusion criteria
-Elevated CRP (>10 mg/L) and strong Gd uptake on baseline MRI
-age 16 to 50 yrs.
-Ileal Crohn’s disease failing immunomodulators and/or steroids for at least 3 months



Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Exclusion criteria
-Significant prestenotic dilation of the ileum on baseline MRI
-Resection of more than 100 cm bowel
-Presence of abdominal abscess



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Crohn's disease
MedDRA version: 8.1 Level: LLT Classification code 10011401 Term: Crohn's disease
Intervention(s)

Trade Name: remicade
Product Name: remicade
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: INFLIXIMAB
CAS Number: 170277313
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 5-

Primary Outcome(s)
Main Objective: To study changes in the inflammatory and the fibrous component of ileal segments in patients with ileal Crohn’s disease treated with infliximab at wk 0,2,6 and q8 wks thereafter.

Primary endpoint:
Number of patients achieving a clinically significant change in MRI enteroclysis score of severity in Ileal Crohn’s Disease (MICD); defined as an improvement of at least 2 points and at least 50% on the inflammatory subscores. i.e. 4 to 2 or 5 to 2 or 8 to 4 (subscores defined in section 21), as measured with contrast enhanced MRI enteroclysis (procedures defined in the MRI study manual) at week 26 compared to baseline.
Primary end point(s): Changes in bowel wall thickness and inflammation on contrast enhanced MRI enteroclysis at 2 weeks and 6 months compared to baseline.

Secondary Objective: To study:
-Clinical efficacy of infliximab in patients with ileal inflammatory stenosis based on CDAI remission and CDAI response (drop of 100 points or more).
-Safety
-Quality of life
-predictors of response (CRP, Gd enhancement on MRI, duration of disease, con meds)
-2 year resection rates
Secondary Outcome(s)
Secondary ID(s)
2006-004784-58-BE
MRI-0143
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history